lauren@drughunter.com
Recent Articles by Lauren
A Deuterated Ruxolitinib Derivative Among 14 Other Recent Notable Molecules
Here’s a preview of two molecules acquired in January 2023 among 14 mentioned in this article: deuruxolitinib (CTP-543) This molecule, a deuterated version of JAK1/2 inhibitor ruxolitinib (Opzelura, Incyte), has received Breakthrough Therapy designation from the FDA and is being acquired by Sun Pharma via Concert in a $0.576B transaction. The oral molecule is in…
Not Your Grandparents’ Drugs: How Approved Drugs Have Evolved Since the 70’s
We recently explored how the lipophilicity (logP) of drugs has changed over time and found that, on average, drugs have become more lipophilic through the decades, primarily attributable to the industry’s move away from natural products. Despite this shift, it is clear from a broad qualitative comparison of structures from past decades to today that…
Two Potential Upcoming Approvals and Other January NDAs
Our latest roundup of small molecules in the news includes two potential upcoming approvals: rezafungin Rezafungin (CD-101) is a once-weekly IV antifungal agent and next-generation echinocandin (glucan synthase inhibitor) that demonstrated non-inferiority vs. standard of care caspofungin (IV QD) (NCT03667690). An FDA AdCom voted 14 to 1 in favor that Cidara (CDTX) showed enough evidence…
Molecules in Motion: An Oral G12D Inhibitor and Allosteric Cbl-b Inhibitor Entering Development
Our latest roundup of small molecules in the news includes three molecules moving into development for the first time: MRTX1133 Mirati’s reversible, long-acting KRASG12D inhibitor, and December ‘21 Molecule of the Month, is going into the clinic as an oral compound. While initial disclosures referred to its potential as an IV agent, Mirati recently announced…
A Billion-Dollar Aldosterone Synthase Inhibitor, an Oral KRASG12D Inhibitor Entering Development, and 14 More Molecules in the News
In this update of small molecules in the news we will cover recent: Want updates like this straight to your inbox? Sign up for our weekly newsletter here. Million-Dollar Molecules baxdrostat This highly selective, oral aldosterone synthase (CYP11B2) inhibitor is being acquired by AstraZeneca via CinCor in a $1.8B transaction. The molecule is in several…
2022 Molecules of the Year: Nominate!
The final set of Molecules of the Month for 2022 is out, and now it’s time to nominate your favorite molecules for 2022’s Molecules of the Year! Nominees should have either been first disclosed in 2022 or had a major new update in 2022 (e.g. clinical trial readout, publication, business transaction, approval). The molecule must…